CDH1 and ovarian cancer: On the other hand, many clinical studies on ovarian cancer [25,26], bladder cancer [27], breast cancer [28], and hepatocellular carcinomas [29] have shown that E-cadherin loss indicates an invasive characteristic of carcinoma, tumor progression, and poor prognosis of patient survival.